MAJI STOCK | NO HOLDS BARRED w/Kimi Sugaya, Casey Barksdale, Marvin Hausman, and Matt Dwyer

[00:00:30]Heat.

[00:00:47]Heat.

[00:01:00]Hello, greetings and salutations.

[00:01:02]Welcome back to the BFC where we go into the trenches of the trading world. I hope you guys are all having a great day. This is where we do DD from the source. Today we have a whole round table planned. But first, hey guys, if you are an ex or Facebook, please be sure to like and repost this content. We want to get as many eyes on the OTC as we move towards the third quarter, aka the summer months. And I'm so glad we are now uh approaching summer and getting into it because it's been a long winter and a long spring. So, and I have a feeling many stocks will be heating up. So, make sure you are liking and reposting. Okay, let's not waste any more time. Uh let's bring in the CEO of Nexttel Medical, OTC, ticker M AJI, Matt Dwire, as well as Dr. from Marvin Houseman who's a returning guest, Dr. Kimmy Sugaya and Casey Barkstdale. Let's bring him in.

[00:02:00]Gentlemen, welcome to the BFC. How are we doing?

[00:02:03]>> Good, Eric. You >> excellent. Excellent. Well, Matt, you are the CEO of MAGI. Uh, and so why don't you introduce your team to us and have them go around and, uh, tell a little bit about themselves.

[00:02:15]>> All right.

[00:02:17]Uh we have Dr. Marvin Houseman who's our chief uh science officer. Uh sorry actually sorry chairman of our advisory board for this company. Um so Marvin why don't you tell everybody about yourself?

[00:02:31]>> Sure. Um I'm a medical doctor from NYU School of Medicine. I was a general surgeon. Um I was drafted into Vietnam and then I went to NIH. made several discoveries at NIH and ended up um being contracted by Bristol Meyers International, formed a company called Medco Research. We then went on the New York Stock Exchange and we're currently a division of Fizer. Uh I'm a transplant surgeon from UCLA in Cedar Sinai and my specialty was newborn babies with kidney defects. I'm specialized now in pharmaceutical research and it's a pleasure to be part of the organization that Matt Dwire has put together.

[00:03:15]>> Thank you, Marvin. Next, we have Dr. Kimmy Sagaya who would be the first time anybody's heard from him.

[00:03:22]>> All right. Hi, I'm Kim Sagaya. I'm a professor of the medicine at the University of Central Florida.

[00:03:30]>> Oh, muted.

[00:03:31]>> No, we can hear you. We can hear him.

[00:03:34]>> Yeah. All right.

[00:03:37]All right. So then the I'm also the head of the neuroscience. I've been neuroscience 80 year of the research more than 45 years now. And then uh I originally from Japan and then uh I was a neurosurgeon in Japan but I switched to the research to help more people than the uh surgeon can help. So uh today I'm so much excited and then uh actually I'm the back of this uh all the technology we're going to introduce today.

[00:04:07]>> That is true. And last but not least we have Mr. Casey Barkstdale from the two companies that we just signed to acquire and jump start.

[00:04:17]The floor is yours.

[00:04:18]>> Yeah. No, my name is Casey Barkstdale and thanks for having us on on the show and you know really excited about the group and the team that we've put together that I think is going to take you know medicine and testing and and patient outcome into you know the next 25 years which is special to me. Um I founded uh Jumpstart RX also founded New Vistrad originally came from a sports background. So in building the companies used a lot that I learned from coaching to to build the companies the same way.

[00:04:51]So you know once again I echo excited to be part of the team Matt's built with Dr. Kimmy and Dr. Marvin just to see what what we can do to help you know patients across the country. So >> excellent. Uh, thank you guys for those introductions and I I want to start with Casey actually. Could you expand on the two recent acquisitions and how they will benefit Nexil Medical?

[00:05:14]>> Yeah, absolutely. So, >> um, Eric, I don't hear Casey and Kimmy.

[00:05:19]I hear him. You, Matt, and myself.

[00:05:27]>> It's It's definitely a setting issue.

[00:05:29]Um, there's nothing I could do on my end.

[00:05:34]It's it's it's probably a setting issue on their end or your end. Um >> I hear you perfectly. I hear Matt. I hear myself. I don't hear Casey and I don't hear Kimmy.

[00:05:47]>> I can't hear.

[00:05:47]>> I'm looking at my settings. It looks okay.

[00:05:52]>> Okay. Uh Dr. Sagaya, can you hear Casey?

[00:05:57]>> Yeah. Yeah.

[00:05:57]>> Okay. So, yeah, that's on your end. It's a setting on your end. I'm I'm not sure. I can't >> Marvin, why don't you log out and log back in. Can you do that?

[00:06:08]>> That's what I'll do. I'll log in and come back in.

[00:06:10]>> And we do have somebody that is watching. Yeah, we have somebody that's watching. We hear everyone in the group.

[00:06:14]So, that's the most important thing is that they can hear they could hear us.

[00:06:18]>> Um, >> but go ahead Casey. Just go. I want to keep things going here. So, um, >> absolutely. So, so New Vista Med was a company that was uh started a couple years ago, two and a half years ago that was set up um it's under the brand Island 40 Group, but it was set up to essentially become a one-stop shop or be able to touch everything inside the clinic space. So, as it sits today, clinics don't necessarily have a lot of buying power, whether it comes to medical supplies, medicines, um, testing, labs, anything that goes on in a lot of these clinics because they're one location or two locations. So, when we built New Vistra Med, we wanted to be able to help expand them to give them buying power and essentially a one-stop shop for anything they may need to to help their patient or to help their business. Um that was the reason New Vista Med was set up. Um as far as Jumpstart RX, it was actually built to help employer groups and to also help um other groups that came to us that needed help with, you know, certain medications or a tele medicine platform, whatever they need to enhance their bottom line as an employer group. also set up for friends and family to help offer access to drugs, testing, and other things, >> you know. And my my next question was was asking on behalf of shareholders who aren't uh health care professionals, which is all of us, most of us, I should say. Explain why Jumpstart RX and New Vistrad are more than just teleaalth companies. I know you touched a little bit on it there.

[00:07:54]>> Absolutely. So when you look at New Vistramed and Jumpstart, both offer end toend customer solutions. But as it relates to New Vista, it's way more than a tellahalth company. If you want to be a marketing company, let's say you want to advertise online or you want to launch a new product, you come to us. We already have everything in a box ready to deliver to you to be able to roll out your marketing team to grow business and to reach the database you're trying to get. as from a if it was just a teleamemed then we would only offer um doctor services or medical services right there on the spot. We wouldn't offer the end toend solution which is what we offer currently.

[00:08:35]>> Right on. Uh well, what if anything can you tell us about the third acquisition you guys are working on? And I'm I'm posing this to Matt and Casey.

[00:08:44]Um, we're working on the paperwork on it, but Casey, you can give like a brief overview of what it does because it's really different than the other two.

[00:08:55]>> Absolutely. So, if you look right now at employer groups, if you look at um let's look at the college landscape of basketball, right, or football with NIL, when you look at sponsorships. So what we did was we saw a a need in the in the space and the name of this company is Mascot Alliance, but we saw a need in the space to be able to offer a true return on investment to people who sponsor and give money to projects. An example of that is if if we go into your business and we can change your business's bottom line through health services or through other health products, then we work with you to then give some of that savings to your college or to your charity or to your nonprofit or whatever. So, we're truly creating a win-win across the board. We also are able to go in with that same company because it is a health services company in a lot of ways. We're able to go into hospitals and to other groups and give them five key areas of savings that we can save them with a turnkey solution. But the whole key to this, Eric, and I want to mention this is we don't displace any of their current partners because I think you would agree the hardest thing is to go in and get someone to change a vendor or change a partnership that's their cousin or their husband or their uncle. So in our case, we don't displace any of them. We want to be everybody's friend while providing better solutions.

[00:10:22]>> That's awesome. Very good. And Dr. Hman, I hope you could hear everybody at this point.

[00:10:27]>> Oh, yeah. No, everything's perfect. I signed back in. It's perfect.

[00:10:30]>> All right. Excellent. Excellent. And I I want to talk a little bit about revenue because, you know, as an investor, as a trader, revenue to me is important. A lot of times you see you invest in these companies and, you know, they promise revenue. They promise they promise and they never achieve that. And investors, you know, they they've heard many OTC companies talk about future revenue.

[00:10:46]Nexttel now claims an immediate $135,000 a month baseline. All right. What is the timeline for that revenue to begin appearing in the actual financial statements?

[00:10:57]>> All right. Well, why don't we do this because we have the man right here.

[00:11:00]Casey, what are your monthly numbers with new students? I'm starting out.

[00:11:04]135.

[00:11:04]>> Yeah, we're right around 135 to 140 uh per month right now. Um >> he's got some things that we're not going to discuss now that are come on that should roll those numbers up and continue to make them grow on a month- over-month basis. Um you've heard us talk a lot about the $4 script program.

[00:11:25]Uh they're waiting for a final check.

[00:11:28]What do you figure? 60 90 days maybe more.

[00:11:31]>> Yeah, I'm hoping I would say, you know, because you're always waiting on inspections and stuff like that.

[00:11:35]Naturally, it's out of our control.

[00:11:37]We're hoping between 60 and 180 days we will be or 120 days, I'm sorry, we'll be up and up and running with with no problem.

[00:11:46]>> All right. So then his estimate on that is approximately 2,000 scripts a day at $4 a script. Everybody can do the math.

[00:11:53]Approximately 300 days a year. So when's it going to show up on on Magic Fins? So we're attempting to close by August 1st.

[00:12:03]So let's just say we close by August 31st. So we'll have a month of revenue which is September post for the third quarter and then a full fourth quarter re will show on the books.

[00:12:16]>> Yeah, go ahead. Go ahead.

[00:12:17]>> I'm sorry. The one thing I will say, I think the interesting part to this, and me and Matt have talked a lot about this when we started talking about this partnership early on and what it could look like is, you know, everyone uses the term biotech, biioarma company, however you want to use that, but the thing that normally happens, and I heard Matt touch on this the other day, is a lot of times biioarma or biotech companies are designed for the home run.

[00:12:42]They're going to burn through capital, burn through capital till they get to the home run for their shareholders. We look at ourselves as a very unique cutting edge biotech company and we have singles, we have doubles, we have triples, and then you're not burning cash. You're you're you're generating cash and then hoping that the home runs that that Dr. Kimmy and Dr. Marvin have create the what you're looking for as a as a shareholder. So, you get the best of all worlds.

[00:13:10]>> You know what? And it reminds me of going to a game because we were talking about baseball backstage before the show, watching a team full of power hitters and them not connecting for the whole game, which was pretty boring. Uh, you know, but to have that intermittent revenue and have those singles and doubles like you're talking about, I think that's absolutely crucial. And I do want to follow up. Uh, you you mentioned a baseline and so where is the the high end of that that you think I mean is the sky the limit really? You know, I think it goes to what we're building from like I mentioned earlier about creating and being able to create the whole ecosystem when you walk into a clinic or when you walk into a practice, right? So, when I look in a walk in, how can we generate revenue and give them buying power on every single thing they touch within that clinic? So when we look at building businesses especially in the in the pharmaceutical and health space I always say number one our focus is always patient outcome right I think we've lost sight of that in healthcare today I think patient outcome number two is um how can we create a distribution channel that is second to none meaning where you gain the trust of your of your distribution network that they know that anything you bring them has already been a vetted and b it's going going to generate the most bottom line revenue for them while helping their patients, right? And then I think the last thing is goes back to what I just said when I look at something coming from a basketball and sports world is how can I touch everything inside of there to where we're able to help them but also help us generate revenue.

[00:14:47]>> And just to follow up on on that, Eric, Casey, I think we started talking when, like last November, I think it was.

[00:14:53]>> Yes, sir.

[00:14:54]>> About that October, November of last year.

[00:14:56]>> Yes, sir. So, we've had multiple conversations. We've looked at different ways things that we're going to expand on here shortly. We'll work with his distribution network. So, it wasn't so much of for Casey, I want to just sell my business and walk away because he's not he's staying, but how can we add to what he's doing and how can our products help his clients?

[00:15:19]>> Got it. Excellent. And uh my next question, actually, this is a question I've been wanting to ask. This is uh the Nano DNA test. All right. Um, the screening test may be the most potential disruptive thing that Nextel has announced. Uh, where exactly are we today between patent approval and actual commercial sales?

[00:15:40]>> All right, I'm going to let Dr. Sagaya handle all the science on this. I'll handle the patent and the commercial.

[00:15:46]The patent was granted. The patent was granted, I think, in 2021.

[00:15:49]>> So, it's already patented.

[00:15:51]>> Fully patented and protected. Could you post just real quick? Could you post that um online on act so I could share that?

[00:16:00]>> Yeah, I'll get you the patent number.

[00:16:02]That's >> awesome.

[00:16:03]>> Uh as far as commercial sales go, what I touched on the other day is and and Dr. Saga will expand on it is we need to file an IRB. We need to run a test against people who have cancer, test them against people who don't have cancer, and he'll explain how all that works.

[00:16:21]And if all that done at the end and he says we're, you know, like his initial test was, then we're ready to go to commercialization. So with that, I'm going to hand it over to Dr. Sagai who can explain the science and how it all works.

[00:16:32]>> All right. Yeah. So this technology very exciting because the noninvasive, you don't have to even stick the needle to your skin. We don't need the blood, right? So then we just use the saliva which is you just speak on it and then the uh we're going to analyze the exoome. Exoome is a small particle released by your body cells and then the particularly we're going to look into the uh those exoome that's the size of the nano particle that means the viral particle. So then the uh that's going to pass through whole your body and then the that's gets into the your saliva that's why we can detect those and then the we can detect the one uh released by the cancer cells anywhere in your body and then once we detect that you have a cancer I hope not but you have a cancer after that we can detect the we can analyze the exome father we can tell where you have the cancer and then these things could happen very sensitive way.

[00:17:38]Uh you know the uh most of the cancer especially the brain cancer you have to wait till the cancer become like 1 cm size or something but the uh this method can detect those things in few cells.

[00:17:54]So then the if you body your body start making the cancer we can detect those and then we can tell where it is. So that's the things we can do without any pain. So that's the big stuff. And then >> it's a game changer. Keep going. Keep going.

[00:18:12]>> Yeah. And then the uh at this point we believe this is the uh you know very uh strong uh patent but the to get the FDA approval we need to do the clinical trial. So then uh we have to prove this one is true with the human uh you know the patient. So that's the uh Matt was talking about and then uh yeah I'm uh the chair of the ILB as well. So then the uh we know how uh to do this process and so on so on. So then the uh yeah actually the uh yeah already we have a two drivers uh already talking about but I'm going to be the like engine for this company and then the uh matter of fact already I invented uh more than 70 patents uh in this uh past 20 years. So then I have a lots of technologies to bring into the market and then uh yeah that's going to help this company too.

[00:19:20]>> Wow that's imp that's impressive. So many pension when we release the screening test we'll be able to detect but we'll just we can't actually say they have cancer. We need we could tell them that uh basically you've got something you need to go see your doctor for.

[00:19:38]>> Okay. Yeah. before we did the FD approval. We cannot say this is a diagnosis or anything.

[00:19:44]All right, that's the rule. So then the uh uh first we want to do the screening lab test in the lab test we can uh say that oh you may have cancer >> and then the uh but the uh that's depend on the ILB setup. Usually the ILB doesn't tell the individual you have a cancer or anything because they after we went through all the research human subject research then we can tell and then we can get approval from the FDA to say oh you can tell this is the diagnosis and then you can tell the you have the cancer or not. I mean, just just to follow up, I just got to say, so you do the test. I mean, does there is there a lot of intermittent time wasted because I know like sometimes they go for the screening and then they got to wait, then they have some people have to have surgery. I mean, like, how much time is this going to save and how many lives do you think? This sounds like crazy.

[00:20:46]>> Okay, you can speak, >> especially if it's just a saliva test.

[00:20:49]You know what I'm saying? you can spit in the tube at home and then they just mail it and then we're going to do do everything in the lab without you know uh any delay. So then the hopefully you know uh once this one uh become diagnosis you can get the results next day.

[00:21:12]>> Wow. And will there be like some kind of a portal you guys are going to work on that it it'll be uploaded to a portal or something like that? Yeah, exactly.

[00:21:19]You'll vacation portal. Once you get the kit, you'll sign up. The kit will have a number and some code you'll deal with and you'll plug in all your information.

[00:21:26]You'll mail in the kit. Then you'll be able to track it along and get your results.

[00:21:30]>> Yeah, we have a question. Uh, when can regular people actually buy and use the Nano Cancer Test? So, what is the timeline for it actually becoming available? Our timeline is if we get the IRB filed here shortly, which we're planning. Uh to get the 100 patients to do the sample test will be fairly quickly. It'll take us one to two weeks maybe to run that many tests, which probably be less. Uh Kimmy has to analyze the results and then from there if he says yes, we're green lit, we plan to launch. So, our we plan to we plan to have this out. It'll definitely be out for October. We're going to shoot for September, but it'll definitely be out for October.

[00:22:14]>> That's excellent. Thanks for the question. Absolutely. Um, I want to to pivot a little bit and talk about the distribution network. All right. And Casey's distribution network. So, one of the biggest things that that caught investors attention was the claim of access to more than 1500 online clinics and 350 physical medical facilities. How active is that network today?

[00:22:37]>> Very active. U we touch over over 300,000 patients within our whole network.

[00:22:44]>> Wow. Is that annually?

[00:22:46]>> No, sir. That was last month.

[00:22:50]>> All right.

[00:22:51]>> No, let me when when you say touch Whether whether it been a tele medicine medicine visit through our network that we we don't own the network. We're just a vendor partner, right? Whether it been a tele medicine network partner, whether it been, you know, one of our clinics, whatever. We're over 300,000 that we can know we've touched based upon purchases or what have you. Like I said, we're the vendor that provides certain things for those um networks, if you will. But that's growing every day from, you know, Dr. Kimmy's, you know, cancer tests to Dr. Marvin to everything we, you know, I think you would agree with this. The hardest time two brilliant guys like Dr. Kimmy and Dr. Marvin have is they're brilliant. They create unbelievable products, lifechanging opportunities, but you don't have a network to to get it to the masses. Um, and and our goal is to be able to provide that.

[00:23:49]>> Yeah, that's that's remarkable. Those are some big numbers and you say it continues to grow. Um, thank you for clarifying that. Um, >> I'm going to add some here.

[00:23:58]>> Yeah, go right ahead.

[00:23:59]>> Um, case you shared a little something with me this morning. It was a a very large invoice um that was provided for uh uh prescriptions.

[00:24:13]>> Yeah, we we just recently invoiced one of our providers, if you will. We invoiced one of our providers um a an invoice of right around $300,000 if you will for it was a little over for three weeks. So just to give you an idea of what the invoicing looks like and what the numbers because I think that's what's important to shareholders. So >> somebody just did a little math.

[00:24:38]>> So So not everything's $4 a script. It's all different. So somebody's math there.

[00:24:46]Although I like it, it we're not talking about that that particular the testosterone. But what we are what we are touching on there with that is the power of the base and when he when product is introduced to it like when you when you first started with them and you turned it on, how quickly did it take from when you turned it on to you be able to to start funneling uh active script scripts over or basically >> I mean it was it look it was a long grind to get where we're at now. I mean, I started by driving around in a Toyota Camry to random clinics and knocking on their door and trying to have something crafty to say when I walked in because I was learning healthcare at the time, right? So in fairness um within 30 days we started seeing revenue and then we've grown it to now and then we've started going back to what I said earlier about being able to provide a end toend solution for people is what they're looking for because at the end of the day the companies that we work with that are teleamemed platforms that we provide end toend solutions or or even our our clinics they want to be able to call one person and know their problem's going to be fixed or one company and it sure does help them when everything inside of their clinic comes from one distributor.

[00:26:05]It changes the world now because we're able to produce and I think everyone would agree there are a lot of people brokers that walk into places and promise things that never can deliver anything. They just promise them, right?

[00:26:18]the success and the reason we've been able to get contract after contract and people allow us like the talk of testosterone of 2,000, you know, vials a day depending on the size of the vial is because they know we're going to move that product through one of our distribution partners, right? So therefore, they're willing to give us that allocation to be able to do that.

[00:26:40]>> I want to touch on one more thing, Eric.

[00:26:42]So when we launch the screening test and we show them the science behind it and um it proves out to be everything Dr. Zagaya says and they like it. What do they like to do with products that they tend to like? One of your main clients.

[00:26:59]>> Who are you talking to me?

[00:27:00]>> Exclusivity. So, so our clients, our clients will pay for exclusivity for for very niche products because >> okay, >> once again of the reach that they have, they don't want to compete with anybody else at least for three months or six months, right? But what that allows us to do is be able to capture some revenue upfront, but then it also allows us to hold them to numbers to keep that exclusivity, >> right?

[00:27:29]>> That's crucial. That's absolutely crucial.

[00:27:32]>> I think >> that's why that that's why we had to bring them in. We had to get the deal done.

[00:27:37]>> And I knew I knew we wouldn't get through one podcast this month where the the word exclusivity wasn't mentioned, which I could actually say now without stuttering on it, guys, just so you know. Uh I I always joke because I always say that's the one word that always trips me up. But uh there you had it. No, excellent answer. And that's act that's pivotal. Um I want to talk about Maxisome uh and the commercialization going on there. So Marvin, finally you could stop being a fly on the wall and and and uh give us give us something.

[00:28:03]But but Maxisome has has been discussed as a major future product line. What makes it different from the hundreds of wellness products already flooding the market?

[00:28:12]>> Well, let's let's go back to what an exoome is or a maxazoo is our proprietary name for an exoome. You have to look at exoomes as the communication system in the body. Talk about a baseball game throwing the ball from first base to second base. Well, that's what these cars do. Exosomes are like little cars moving around the body. They communicate between cells. And that's beautiful. What Kimy's working on, I want to diverge just for a second.

[00:28:43]Cancer cells are communicating with the saliva. How do they communicate? They communicate through these little cars called exoomes.

[00:28:53]It's the communication.

[00:28:55]When you have arthritis, how does the arthritis communicate with your immune system through exoomes?

[00:29:04]And so what we're doing with maxazomes is isolating from food substances like mushrooms. And you know how important lion's mane is. It's one of the top selling things on the online internet.

[00:29:20]or yellow oyster. So, I've established a relationship for the company with Hershey Medical Center and Penn State University, which is the top food science university in the United States to analyze exoomes from mushrooms.

[00:29:38]>> So, when you eat food, there's so many other products in the food. What do these small cars communicating from the food carry? And so we now are the first company to analyze and we're looking at things like beta glucans, polyphenols.

[00:30:00]I don't want to bore your audience, but we're going to create a pamphlet, a white paper to explain all this. When you take on maxazoo, what are you getting?

[00:30:13]And remember, this is like targeted delivery.

[00:30:17]This is like Whimo, you know, like this is the Google thing, the car traveling around your city delivering food. Uber.

[00:30:24]So, we're developing an Uber system using Exosomes.

[00:30:29]>> Do you think there's code there with these little cars? You and thank you for explaining it like that. Here I am explain it to me like I'm a first grader. Do you think there's code there or ha um uh not habits but data there I guess that could help reverse cancer or arthritis or stuff and and not even reverse it but help address it better.

[00:30:52]Is is that where this is going because almost like reverse engineering the the the telegram you know what I mean?

[00:30:58]>> Yeah. Just just an example Kimmy was talking about his saliva test which isolates nano. We have already proven this and Kimmy has in an animal model where he has taken exoomes and genetically modified them and then he was able to show that these exoomes genetically modified increase the efficacy of teosomide can mers drug for cancer. So we've already shown that I've taken that data and through the company we've applied to the FDA. We already have often drug designation for that technology and then we applied to the European Union and just two weeks ago we got approval in the European Union for that technology.

[00:31:46]So this is cutting edge. We're now opening a whole new door and that can work beautifully and integrate with Casey's because patients want advocates. They want people to explain to them how they could live longer, how they could. So when you try to call a doctor, it doesn't answer the phone.

[00:32:11]>> And so we hope to bridge that gap.

[00:32:15]>> And this Exoome is the communication opening for Casey's patients. So Marva's going to concentrate on products specifically within the wellness industry which will help with Casey's distribution line. But one thing Kimmy's working on for us for the maxazoo is through a discussion he I and Marvin had the other day where we have to now do an IRB study because and I'll Kimmy to explain it better but uh we want to give product and then vary the dose and the amount of exoomes and I'll let Kimmy explain it because he's the doctor.

[00:32:52]>> Oh okay. Yeah. So then the addition to the uh you know Marvin to uh exoome can deliver the things even to the brain. So then the everybody in this world they try to even the big farmer they try to deliver the drug to the brain that's very difficult because we have a barrier between the brain and then the other part of the body. So then the but this exosome can deliver those things that's a big big big you know advantage. So then the uh even uh uh we talk about the testosterone okay uh to deliver the testosterone to the brain that's kind of things we can do and then why that important libido you know energy emotion those things are happening in the brain so then the that's the totally separate out distinguish ourself from other product and then uh uh for this uh you know the M talking about the uh clinical study.

[00:33:56]Yeah, we want to have uh scientific proof. So then that's the reason that we want to change the dose uh between the people and then uh ask the people how much got affected or something and then to do that again we going to go through the uh strict ILB regulation and then we want to show the proof of this product.

[00:34:19]So that's what uh uh we want to do.

[00:34:22]Excellent. Excellent. Matt, did you want to add anything? No.

[00:34:26]>> No, I can't follow that.

[00:34:27]>> I know.

[00:34:29]I I want to talk about uh one of the most recent PRs. Um the Penn State validation. All right.

[00:34:36]So, Dr. Hman, the Penn State study sounds groundbreaking, but investors have seen many early stage biotech announcements before. Um you know, we were talking a little bit about this as well, but why is this particular study so important?

[00:34:51]Well, because there were everything in life has a genetic background.

[00:34:57]Mushrooms date back. They're prehistoric. They go way back in life.

[00:35:02]They're part of the basic food source of life. So, if we identify yellow oyster, what is the genetic background of yellow oyster? What is the genetic background of lion's mane? And we show that this particular genetic entity produces these powerful exoomes which we now will have.

[00:35:24]We're ready to launch um for example in in one cc of fluid or say 10 cc's we have about 180 billion exoomes from mushrooms. This is a definite food source, a supplement that humans can use and it's a great marketing program with Casey's to integrated into Casey's program. My god, it's like a dream come true. Mhm. I I want to >> and may I just add in answer to your question, Eric, >> we're going to file patents on all this to protect the technology and I've spoken to Matt about that and so we're this is going to be something and I've spoken to Dr. Sugay about this also.

[00:36:09]>> Yeah.

[00:36:10]>> When I saw this study >> when I saw this study I couldn't believe it. So that's a very amazing you know the what the point amazing is that original mushroom itself you know when we eat it we get the some effect. Okay but what we found here in this study was the exoome capture those goodies more than the uh you know high concentration than the original food.

[00:36:38]That's the amazing I didn't expect that.

[00:36:41]So then the that's the uh things and also the by you know those things got into the extra zone easy to get into the body and then the those things are protected by our body for example like uh uh easy thing is the stomach acid going to destroy everything but uh if we put in exone it's going to be preserved so then that's the another good things even the these things we could you know put into the nose or under the tongue that's where the exosome even penetrate into your body. So then uh that makes uh uh those two things you know very significant different from any other product.

[00:37:32]>> We're ready to launch based on what Kimmy is just saying. We have our freezers full with these exosomes and so we're just trying to set up the marketing program and I want to work closely with Casey to set up an integrated marketing plan with his organization >> which we'll have a big meeting on that in July that we're already scheduling.

[00:37:54]But going back to the the research, Eric, so what Kimmy and and and Marvin are finding from that are different applications than the ones we're currently working on. So Marvin has always said that um the exoomes themselves, like for myself or you if you took your hat off, we rubbed it on our head, it would help our hair grow.

[00:38:20]But Marvin's also said if you Yeah.

[00:38:23]inject it in, then it will it will really work. So, we're doing our sterility test, as you know, that I talked about the other day, and we're find we're finishing that. When we have that completely done, Marvin's going to run some other tests in the lab. He's going to send me a bunch of vials, and I have a doctor who's actually going to inject it in me to we'll see if it grows hair, which hopefully it will. But one of the other things is a lot of people right now they're using peptides for regenerative growth for muscle issues tears. So I have tears in my shoulders that I currently use the Wolverine stack peptide in but I want to use our exoomes in there because I think they're actually a lot stronger. And if you go to a sports clinic now where they are doing exoome injections, these are the mamalian ones, the human ones. I went to a place and for a package of five injections, it was $15,000.

[00:39:26]So I looked at the guy and I said, "Well, I'll just bring my own. Just give me the injections, you know." So that's these are things that are coming that are already being worked on that we haven't discussed but there's a lot of products outside of like one two or three that we're going to come out and a lot of them will go through Casey sales shows.

[00:39:50]>> It's it's remarkable. You got the innovation of ground breaking science and then taking that and tapping into Casey's market. It's like >> it's remarkable. And I just want to finish one thing with Penn State. One thing Marvin and I have been working on is >> Marvin's a big fan of kloids. He'll sit here and talk to you for an hour about a kloid. Um, a kloid is a growth on the body. So, I have a a friend in Miami who's probably if not the top one of the top three laser experts in the world.

[00:40:21]So, we've been talking back and forth and she's ready to work with us and partner with us on a study for how our exoomes can help heal the skin after laser therapy and help with the removal of kloids. So, Marvin's been waiting for this data to come back from Penn State for us to move that forward.

[00:40:42]>> Yeah. No, this is fantastic. We just got the data and Dr. Bitser who is the head of the department at Hershey is now analyzing the exoomes for additional biologic active molecules like vitamin D, heavy metals, selenium, zinc, all the things that your body needs and that we just got data which Dr. Sugaya mentioned that betaglucans may be higher in the exosome than in the parent food where the exoomes came from.

[00:41:16]>> Now think about what the significance of that is. We know that betagon glands are very important in wound healing.

[00:41:25]And if a if a dermatologist excises using an eczema laser, a koid, this is a whole new arena to take this exoome serum and put it on the wound >> and activate healing.

[00:41:44]>> Yeah.

[00:41:45]>> And we're sitting on these compounds.

[00:41:47]We're ready to launch.

[00:41:48]>> Yeah.

[00:41:48]>> Matt and I have to go down to see the doctor in Miami and set up the study.

[00:41:55]Yeah, that's true. And also the uh lion's mane uh it's known to increase the DDNF which is the uh goodies for our neurons.

[00:42:06]But unfortunately when we eat it, it not going to go into the brain. So then that's the problem. But with this exosome that directly gets into the brain increase your you know those goodies in the brain. So that makes us so much different. Would you say >> this is an area we're going to find paths on? So we have to be careful talking about it.

[00:42:29]>> Would you say that's as beneful as using like MCT oil?

[00:42:34]>> Ah yeah MCT oil. Yeah actually it's better I think.

[00:42:39]>> Okay. Yeah. So Oh no go ahead.

[00:42:44]>> Oh go ahead. What?

[00:42:46]>> I wanted to just continue on the patent mode. That's what I wanted to talk about a little if that's okay.

[00:42:51]>> Um Go ahead.

[00:42:53]>> No, no. Dr. Houseman, a Matt has mentioned new patent filings potentially resulting from the Penn State research.

[00:42:58]So, how important is intellectual property to Nexel's long-term strategy?

[00:43:03]>> Very important. I had mentioned it earlier. I I I called the mushroom manufacturer. So, they a mushroom is produced from spawn like the sperm produces humans and ova. Mushrooms produce their own spawn, but there's a genetic background to the spawn. So I'm waiting for a phone call from our manu from this large one of the largest mushroom farms in Pennsylvania dates back to the Revolutionary War. I'm waiting to find out. I just had a call with them on Thursday last week to see what is the genetic background of the spawn that produced the lion's mane that has the highest level of this product that could stimulate BDNF for example in the brain. Mhm. Mhm.

[00:43:50]>> So we when once I get that data, we're going to file immediately patents and protect that.

[00:43:56]>> Yeah. I got a new idea from there. But I wouldn't tell I wouldn't tell.

[00:44:01]>> Don't tell anyone.

[00:44:02]>> I was going to say you're not going to he's not going to say anything. He's keeping it in the vault. He's saving it.

[00:44:06]>> That's another part another you know uh things. Yeah. Eric, I think I think the important thing about investing in us and investing in our team because I always say as much as you're investing in a business, you're investing in people and a team, right? And I think that's always been important. I think the thing is you have two very brilliant gentlemen on this call here that are brilliant. And I think the one thing and you're going to hear, you know, you've heard them talk about many of different things that we have access to or that we can do, but the one thing I want to promise the shareholders is we're going to we're very organized about how we're rolling this out with a plan. So everything we roll out is totally buttoned up, ready to be marketed, and there's a complete plan for distribution. And I think that's important because a lot of times you can hear all these different things, but there's no real organized plan of a roll out. It's just all over the map to try to make a dollar. I think we're going to be different and I know we're going to be different because we're going to be very organized in some of the calls our teams had on this.

[00:45:11]>> And to expand on that, Eric, Casey, you already to expand on that, you already have a whole marketing team put in place, >> correct? We don't have to go put that together.

[00:45:20]>> I did ask Yeah, I asked that during the spaces, too. I know. And so, I'm glad.

[00:45:25]>> Yeah. And and then one of the things I heard that Matt got asked on I think it was Thursday's show. I may be mistaken, but I think that's right. Was, you know, having everything set up, boots on the ground already. We already have that.

[00:45:39]And as we as we grow and expand, yes, we're going to have to bring on more team members and stuff like that to cover the different offerings that that Dr. Kimmy and Dr. Marvin bring to the table. So the same guy that's servicing or same lady who's servicing clinic Y may not be a fit for hospital A. So we'll have to bring someone in that fits hospital A. That's that's how we're going to build this thing for long-term success.

[00:46:07]>> Yeah.

[00:46:09]I don't want to lose track of something you said the patent. Just think of a car. I said that these exosomes are cars. Remember that cars have doors. We can open the door on the exoome and put passengers in there. Think about that.

[00:46:27]>> So if we come across a formula, a NASA formula for muscle regeneration or wound healing because remember these astronauts go up in space and they get sick up there and and zero gravity is a problem.

[00:46:43]>> So these cars are turning into like little Trojan horses.

[00:46:47]>> Yes, absolutely. for targeted delivery of these key peptides, key amino acids.

[00:46:54]We should not look beyond this and and we file patents that are owned by the company in this area. We didn't forget about any of this. So, by opening that car door and loading it in, we have filed a patent and we've took all key bioactive substances that are known to medicine and they're in that patent and how we load or open that car door and then close the car door.

[00:47:23]>> So, that is what we have in simple terms in this company.

[00:47:28]>> Yeah. Excellent. All right. I want to keep uh I want to keep it going and actually cuz um I did want to just one more thing and then I I got a hammer matt on a bunch of questions which I promised people I would do whether he likes it or not. So um I I do want to talk a little bit. I was doing a little research on that and you know the FDA has repeatedly warned consumers about unapproved exoome products and you know some scientists argue that commercialization within the exoome industry has moved faster than clinical validation which is something that you guys are already working on. Um, given those concerns, why do what do you believe regulators and critics are getting wrong about the science behind exosomes? You've talked about some of that already. And how is next still differentiating itself from companies that may have already contributed to that skepticism?

[00:48:11]>> Yeah, actually that they are not doing wrong. Some of the company just skip everything and then the you know I cannot believe why they can you know give that kind of things give the to the people you know the even in Japan you know I shouldn't use that word right >> no you're fine >> right so but that's my feeling that's my feeling right so then the even in Japan some of the people they killed the patient with the giving such a uh wrong you know exoome this exoomeia exoome and also they they're making the exoome from the uh what even the cancer cells or they're putting the uh uh bovine serum I mean cow blood things right so then the definitely that's wrong that's why the you know the authorities they start to watching those uh things and then that's necessary but we not going to do anything like that.

[00:49:21]>> When we talk about the human cells we going to use the you know uh stem cells meenyal stem cells from the you know such a subject right and then we never ever use any animals blood you know resource at all. So then those are the total different and then always we try to be scientifically proved. So that's the reason the even we talk about the clinical trial and so on and then from there we're going to check those safety and other things too. So definitely they're doing you know right things they're doing and then we going to do the right things. That's my feeling is >> excellent. Excellent. Thank you for sharing that. And it's better to be correct and efficient rather than, you know, supply a bunch of essentially.

[00:50:13]>> Right. Right.

[00:50:15]ProTC products, you don't need to do an IRB study, but we're going to go ahead and do it just to get >> Well, I think it's important and you guys are are a step ahead, especially in regards to the network you're setting up, the innovation. Things are looking great for an OTC ID company. It's you guys are ahead of >> I have to go now. So, we'll talk later.

[00:50:32]>> You're Just stay stay right there. All right. And I I want to talk about the share. I want to talk about the stock. Since next cell transition, the next cell transition, shareholders have watched the share price continue to struggle despite multiple announcements involving patents, telealth acquisitions, exome commercialization, uh, and Penn State research, which we were just talking about. Why do you believe the market is still discounting MAGI so heavily? And you know what, this is just to piggyback on, you know, I know he mentioned this unboxing bastard with the share price getting hammered.

[00:51:01]Why should shareholders stick around?

[00:51:03]So, why don't you just address that right now if you can, Matt? All right.

[00:51:06]If as far as why shareholders should stick around, if you've been listening for the last hour, that's why. Okay. As far as the stock price goes, yes, we did bring in reggga money. Yes, we did use an individual who I knew how they traded and he traded like he would normally do.

[00:51:28]And his last batch, you know, hit the market, took it down, came back up.

[00:51:35]somebody else got upset, but I think people shareholders are going to see some changes coming here shortly. Um, we'll be a lot more selective moving forward. We had some needs we had to address. There was just no way around it. We dealt with them. We do need capital to continue moving forward. I'm not going to say we don't, but I think we could be a little bit more selective in how we do it so it doesn't And I'm I'm I'm probably dealing with a question that you might have regarding delution, so I'm going to roll it all into one.

[00:52:11]>> Yeah. Yeah, that's why I put this up.

[00:52:13]Yep.

[00:52:13]>> So, we although we will still be issuing reggae shares, they're not going to be at the current price. that I'll say. Um, and I think people will be happy that um, we're moving the price in a northern direction, that we're not going to keep issuing shares down here, that we'll be more selective in the players that we're going to bring in. Um, and I think that will handle both the share price and we're going to structure it a little different so it's not a constant foot on the back of the neck of the stock so the stock can absorb it in, breathe, come in again, absorb it in, breathe, and we're we don't have much more to go, but we do have some more to go. So, like I said the other night, we had 29 million left. We're we're we're not gonna put 29 million out.

[00:53:12]>> Well, and even just look looking at the the share price and looking at the the potential, this stock is a low float.

[00:53:20]The share structure is intact. There's no convertible debt. I think that's people's biggest concern. And you know, there were a lot of pissed-off people.

[00:53:26]You know, when you have this thing, you know, it runs up, it's, you know, in 20 cent plus cents, whatever. And now here we are. So I mean given the science, given the network, given the revenue creation, I think that eventually the share price is going to catch up with what you guys are doing. Um that's just my personal opinion. That's what I hope happens. Um so I just want to follow up with you know just specifically about Deluchi. You mentioned the 29 million mentioned it today, mentioned it on Thursday.

[00:53:56]Okay.

[00:53:58]What what about the reggae offering? I'm just going to jump to the to the reggae offering. Can can you provide on the actual regular offer offering itself?

[00:54:05]Are they still actively selling the share and and how much remains available? You said 29 is still available. That's not what you're available to to be sold today. How much would you do you think you how much would you like would be reasonable where Matt says you know what we out of that 29 we had 15 and based on the revenue we created and the network and the products and the everything getting up to speed studies being done products being distributed 15 was worth it I'm just using that as an example what would be that number where you would be satisfied out of that 29 >> I'd be happy if I only had to do five honestly you The goal here is the goal here is not to flood the market with with equity right now just to grab the cash and get us from A to B which is B is when Casey's revenues start showing on the books. That does us no good.

[00:55:01]>> Everyone on this call right now or on the screen and listening right now is affected every single time we do something. Even if we do like the restricted chairs I put out the other day. Granted, they're not going to hit tomorrow, they're two years down the road or less when we become fully reporting, but when you give shares, whether it's for services or whether it's for money or for this or that, you have to know when you're handing it out, it's coming back.

[00:55:32]It says when's it coming back? And if you can put it out in a way that when it does come back, the market can absorb it because it's just not a constant deluge of of stock like happened that one day.

[00:55:47]Um I think it's treated a little bit differently.

[00:55:51]>> And I think when and I don't expect anybody to to believe anything right now. They're going to have to see it.

[00:55:59]And I think once they start seeing things go in a different direction, then they'll see that we really won't need the 29 million. We probably won't need 10 million. I don't even think we'll need 15. We're a very lean and mean company and we just have a few things that we need to get done to be able to bring one, bring the test out, two, give Casey some product to sell.

[00:56:25]>> Yeah. I I I I want to keep it moving here. Um I you you mentioned before funding without dilution. You've stated the Jumpstart RX and new Vistrad acquisition will be non-dilutive and funded through Lemi Holdings, ticker LMMY.

[00:56:40]Walk us through exactly how that's going to work.

[00:56:44]>> I'll walk you through how how much of it I can.

[00:56:46]>> Okay.

[00:56:48]>> So we own a a a block of stock in in Lambie.

[00:56:54]When Lammy starts having its market going, which I anticipate will be shortly, then it will become an attractive stock and we could and we will offsell part of our holdings to somebody to cover the cost of not only Casey's acquisitions, but I believe I I believe this was in a tweet, not in a PR, but my entire goal is at this point right Now, we put out 21 million so far of reggae shares. All right.

[00:57:30]I I don't Let's just say we round it off to 30. Let's say between now and the day we're done, we issue another nine. So, it's 30 million. Well, part of the leverage on that is going to pull that 30 back out of the market >> because we said we were going to do that. We have the ability to do that. We don't need to wait for cash flow. We can do it from there. That's why we're holding it.

[00:57:51]So, and then once we get the market going there, if there's anything else we need to do to grow Casey's side of the business, to grow what Marvin's doing, Dr. Seaga's going to need new toys in the lab.

[00:58:04]Marvin's going to need toys in the lab.

[00:58:06]They cost money. All right. But there's ways of going around doing that where we don't have to go through the pain we're going through now.

[00:58:18]So there's a once we do that we'll we'll shut it down.

[00:58:23]>> Got it. Um I want to talk about SEC reporting. You've announced plans to audit financials and become fully SEC reporting.

[00:58:31]>> Y is it are is are you going through with it and why is it so important to do that?

[00:58:37]>> Well yeah I'm going through it. I mean we would have done it a long time ago but you know the problem we had with what we had we had to wait two years. So yes, we are going to audit 24 out of 25.

[00:58:49]We are going to audit the first six months of 26. That's why Casey's going through the pain he's going through.

[00:58:54]He's got to go do audits now. Uh and he's engaged uh our auditor and he's already going through that process. So his companies will commit audited. That way we'll be able to roll up together.

[00:59:05]So, our goal is to have an S1 ready and plug numbers in let's just say end of February, beginning of March, file it March, April, May. Probably should be by May. I'm thinking the S1 to get approved. We're not registering any shares to sell. We're just registering the existing shares. Um there was no gap when the company uh ceased being trading before. So they're not going to come back to us for anything there. So we'll go through the standard comment process and and go up. But it's not a company that will get bogged down because we're missing something or we're deficient.

[00:59:47]But the importance of getting it fully reporting is to have the ability to then if we have to tap into capital markets, we can we can do it differently, which hopefully we won't. but more importantly to get more liquidity for the company. You know as well as I do when we get to a fully reporting status, there's a whole different level of shareholder that's going to come in.

[01:00:11]>> Being that we're in the biotech and the health and wellness industry, that thing's doing those sectors are doing nothing but growing right now. Think about that. I mean, think about the number of patients or or uh >> yeah, number of patients that he was talking about for one group for last month and that's just one segment. I mean, it's huge. When you look at the annual growth, when you're looking at health and wellness and anti-aging, that all fits into the products of Marvin.

[01:00:39]And then, I know Kimy's got things going on in his head right now that he'll share with us later on that we'll add to this. So, our goal is to build this as big as we can get it and look to sell it to a private equity fund first quarter of 28.

[01:01:05]>> Okay. Yeah. So the OTC QB uplist uh by quarter one which you were talking about especially with fully SEC reporting that's crucial to get to that point. Um >> yeah.

[01:01:18]>> Okay. And and everything you just mentioned because I was going to ask about what milestones need to be achieved between now and then uh to make that happen, but you just rattle off a bunch of them. And obviously on the operational honestly listening to you guys today on the operational side, I'm not I'm not concerned on the operational sides. I think like Casey was mentioning, it seems like you guys have a very detailed plan. It seems like your communication is great. He has the network. You guys have the innovation, you have the science, um, and the science is being backed up by pens and studies and, uh, you got your university, uh, you got your Penn State thing going on there, which is huge. So, I'm not worried about the operational side, guys. I think that's great. So, I like hearing how you're talking now, Matt. um in regards to how to limit dilution and how to basically get to OTCQB and make sure you get fully SEC reporting which is absolutely huge uh for you guys.

[01:02:07]>> And that's quarter 1 2027 like you said.

[01:02:09]Right.

[01:02:09]>> Right. But you'll we'll produce a audited for 25 and audit review for 26.

[01:02:18]We'll start that at the end of the month in Jan and July. So August, September.

[01:02:23]So somewhere by the end of September, early October, we should be able to produce audited 25 and then audit review. Well, we'll repost those numbers up in uh in OTC. And once we do that, then we can uh file to go um QB listing at that time because we'll have audited numbers. We don't have to be reporting.

[01:02:45]We just need audit financials.

[01:02:47]>> So QB should be by quarter 2ish. No, QB QB should be Q4 of this year.

[01:02:54]>> Okay. Okay. All right. Great.

[01:02:56]>> You can apply once you have audited financials.

[01:02:58]>> Okay. Got it.

[01:03:00]>> And you're over a penny.

[01:03:01]>> I was thinking a quarter in the wrong direction. My bad. Um I I just have a couple more questions. I know we're we're pushing an hour and I don't want to lose anybody. Um many Magi shareholders, as I was saying before, have been underwater for a long time.

[01:03:13]They're frustrated. Some have lost faith. And I know you've taken a beaten lately from them. So maybe people say rightfully so. What would you like to say directly to those shareholders right now?

[01:03:25]>> I'd like to say that it's it's it's tough to explain where we are and what we have unless you have Dr. Sagaya, Dr. Marvin, and Casey put it together like we did tonight. having it here and then not be able to say it. It's difficult, especially in the decisions I've had to make because as I said, 26 is our year. We built, we've designed, we're ready, we have to launch.

[01:03:59]Was it a pricing ideal? No.

[01:04:02]Was it effective to a degree? Yes.

[01:04:07]Could it have been more effective?

[01:04:10]No doubt. But it was a world. It was a situation we had. We dealt with it.

[01:04:16]We're here. Our next goal now is to ensure that nothing else gets issued in this level. Move it up. And I think with the execution of Casey's team and feeding his team what we have, um, I think people will begin to see the revenue numbers, like I said, in Q4, not just from him, but from from, uh, Matthew's products as well.

[01:04:42]>> All right. Um, there's belief among some shareholders that OTC executives often overpromise.

[01:04:48]This is the truth. I see it all the time. They release exciting PR and then you know they move the goalpost but I'm I'm bagged in a lot of these stocks where they just keep kicking the can.

[01:04:58]Their timelines don't line up.

[01:04:59]>> Uh why should investors believe next will be different?

[01:05:04]>> Well, I don't think we've actually had a timeline but and we might we probably have had one that I can't recall right now. I know we had I know we had hoped to do the reggga last year and began funding it at the 1520 level but unfortunately due to events from other shareholders from the past that prevented us. So yes that did move our thing but going from where we are today our biggest holdback from actually delivering anything is just having the cash flow to be able to do it. So by utilizing the tool the reggga a to be able to do the IRB study for the screening test do the IRB study for the products that gives us the ability to then generate revenue within the company. Bringing Casey's company in brings us the ability to to generate revenue for the company. People will will watch Lambie when they see Lambie starting to trade and they see volume starting to go there. Then I think confidence will come in and say, "Oh our our equity does have value." If you notice, and I said it the other day, I never talk about the Lambie shares at all. I don't talk about our Lambie Holdings at all because to me, it's not worth talking about right now.

[01:06:25]Not because there's nothing of value there, but we've been letting it percolate while Marvin and Kimmy work in the background there.

[01:06:35]When will Amy get a website?

[01:06:37]>> Uh, probably within the next two weeks.

[01:06:41]>> Awesome.

[01:06:43]>> That was a cut and dry timeline for you right there.

[01:06:45]>> Oh, we're we're already in the process.

[01:06:47]So, >> that that's good. That's excellent. I bought a last question for you, Matt.

[01:06:51]Uh, looking ahead to the second half of 2026 and into 2027, what are the most important milestones you expect Nextel to have achieved?

[01:07:01]All right. 26. Closing Casey, launching the screening test, getting at least two of Marvin's products out in through his distribution network, delivering an audit and a QB upgrade.

[01:07:17]If we can get all that done, which we should, we shouldn't, there's shouldn't be anything hindering our ability to do that, that should be 26. 27, we should be looking at adding additional products into Casey's downline.

[01:07:35]Um, we should be looking at our S1 getting effective and becoming uh a fully reporting entity.

[01:07:45]Um, and then we should just be looking at expanding our ability to add products not only with Casey, but in other outlets that we have. So Casey's Casey's scenario is a perfect launch for the screening test. And as it launches there, then that would give us the ability then to launch in other areas because if you have a product and you only have 5,000 boxes on the shelf and it goes like wildfire, you know, that's a bad situation.

[01:08:22]Especially when you're a cancer screening test. People don't want to wait a month to get the test. You know, they they'll go on, they'll move on to somebody else. So, we want to have the ability to have the availability to fulfill those orders when we get them.

[01:08:37]So, that's uh that's our goals. That's what we're looking for. At least what I'm looking to do for the company. The men who are driving it are right there.

[01:08:46]It's not me. I follow their direction and we go.

[01:08:50]>> Wow. Yeah. I want to this was a really meaty episode and I am doing a update a a stock update show in about three weeks. So I hope to have you guys all on again just to you know sort of give an update to where we're at and don't ever hesitate if you ever see us doing a spaces and next spaces. Um Casey if you're ever listening in feel free to always jump on and share your progress.

[01:09:12]Um I want to thank all you guys for taking the time. Thank you for the people that were watching that were sharing and or questions and comments.

[01:09:19]Uh great stuff. Uh, and so this this is fun. This is a great time. And uh, so Dr. Marvin Houseman, Dr. Sagaya, Casey, Matt Dwire, always great to have you guys. Thank you so much for for joining us.

[01:09:32]>> Thank you.

[01:09:33]>> Thank you very much.

[01:09:34]>> Thank you.

[01:09:35]>> Thank you.

[01:09:36]>> See you guys.

[01:09:37]>> All right. See you then.